Leuven, BELGIUM, November 3, 2025, 6:00 PM – Oxurion NV (Euronext Brussels: OXUR), a pharmaceutical outsourcing company based in Leuven, announces the termination of discussions regarding the planned acquisition of a company specialized in preclinical microbiology services (see press release dated June 19, 2025 – link). Following a thorough assessment, the company concluded that the conditions required to finalize the transaction were not met.

This decision reflects Oxurion's commitment to maintaining strict strategic and financial discipline in the execution of its growth plan. The Group remains fully committed to its targeted consolidation strategy, focused on high-value-added services in clinical development.

Continued progress on clinical integration

In parallel, Oxurion confirms the continuation of the transaction with a company specialized in clinical operations and regulatory affairs (see press release dated October 13, 2025 – link). Currently in the due diligence phase, this transaction aims to strengthen the Group's capabilities in integrated clinical trial management, in synergy with its existing areas of expertise.

This initiative is consistent with the complementary positioning of Axiodis, a recognized player in biometrics and clinical data management. Together, these entities will enable Oxurion to offer a comprehensive service portfolio combining statistical rigor, operational excellence, and regulatory compliance.

A steady strategy, a clear direction

Oxurion reaffirms its ambition to build an integrated group of European pharmaceutical subcontractors capable of supporting healthcare stakeholders throughout the entire therapeutic product development cycle. The company will continue its efforts to identify and integrate strategic partners aligned with its value creation objectives.

Oxurion benefits from an exclusivity period through December 31, 2025, during which the target company and its sellers have committed not to initiate or maintain discussions with third parties regarding a potential competing transaction.

About Oxurion

Oxurion NV (Euronext Brussels: OXUR) is a company specializing in acquiring majority stakes in promising European pharmaceutical subcontractors. Oxurion's ambition is to build an integrated group of subcontractors serving healthcare players. The Group's headquarters are based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

Additional Disclaimer

The planned investment in digital assets (such as Bitcoin and Ethereum) exposes the Company to specific risks related to volatility, regulatory uncertainty, and cybersecurity. These factors may significantly affect the expected performance of the investments.

For further information please contact: